Drug profile · INN
doxycycline
APX-DOXYCYCLINE
doxycycline (APX-DOXYCYCLINE) is a matrix metalloproteinase 8 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — doxycycline
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 5
- Data quality
- 0.89
Quick answer
doxycycline (APX-DOXYCYCLINE) is a matrix metalloproteinase 8 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Matrix metalloproteinase 8 inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is doxycycline?
doxycycline (APX-DOXYCYCLINE) is a matrix metalloproteinase 8 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for doxycycline?
APX-DOXYCYCLINE is a marketed brand name for doxycycline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of doxycycline?
doxycycline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.